Delivery Order SPE2DB22D3501-SPE2DB25FWV80
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,196.02 to AmerisourceBergen Drug Corp for 4,568,895,450 units of Actemra 400 mg/20 mL vials on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Actemra 162 mg/0.9 mL syringes, with a ceiling value of $23,369.56 and a firm fixed price structure. The delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. Performance is scheduled for...
- The Defense Logistics Agency awarded a $14.3K delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra 200 mg/10 ml vials. This competitively awarded, firm fixed-price contract is scheduled for completion by August 19, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a $13,171.30 delivery order to AmerisourceBergen Drug Corp for 4,568,832,740 units of Actemra 400 mg/20 mL vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Actemra 400 mg/20 mL vials with a ceiling value of $6,595.84. This non-set-aside contract award was competitively procured on a firm fixed-price basis, with an ultimate completion date of August 19, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $3,779.36 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, firm fixed price contract is scheduled for completion by August 14, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 12, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $4,594.53. This firm fixed-price, competitively awarded delivery order is funded by the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency, and has an ultimate completion date of August 13, 2025. The award was made under no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $8,633.52 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is set to be completed by August 1, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving as the place of performance for this federal medical procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWV80Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Actemra 400 mg/20 mL vials with a ceiling value of $2,798.77 and a firm fixed price structure. This delivery order represents a pediatric quantity of the pharmaceutical product and is expected to be completed by August 14, 2025. The contract utilized no set-aside designation, indicating competitive award procedures, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for the Department of Defense's medical supply chain, supplying a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare programs globally. The company's extensive portfolio of federal contracts with the Defense Logistics Agency demonstrates its capability to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains. This particular order for Actemra, a treatment commonly used in rheumatological and immunological conditions, reflects the company's role in ensuring pharmaceutical availability for military and veteran healthcare systems through the Defense Health Agency's integrated supply network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/13/25 |